abrdn plc Makes New Investment in Caribou Biosciences, Inc. (NASDAQ:CRBU)

abrdn plc purchased a new position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 181,487 shares of the company’s stock, valued at approximately $1,040,000. abrdn plc owned 0.21% of Caribou Biosciences at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. State Board of Administration of Florida Retirement System grew its position in shares of Caribou Biosciences by 32.0% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 21,320 shares of the company’s stock valued at $102,000 after acquiring an additional 5,170 shares during the period. Stansberry Asset Management LLC increased its holdings in Caribou Biosciences by 8.0% in the 3rd quarter. Stansberry Asset Management LLC now owns 77,232 shares of the company’s stock worth $369,000 after acquiring an additional 5,737 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in Caribou Biosciences by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 23,924 shares of the company’s stock valued at $137,000 after purchasing an additional 6,066 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Caribou Biosciences by 32.8% in the third quarter. Principal Financial Group Inc. now owns 25,198 shares of the company’s stock worth $120,000 after purchasing an additional 6,227 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Caribou Biosciences by 352.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,226 shares of the company’s stock valued at $59,000 after purchasing an additional 7,968 shares during the period. 77.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright raised their price target on Caribou Biosciences from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, March 19th.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU opened at $3.78 on Tuesday. Caribou Biosciences, Inc. has a one year low of $3.44 and a one year high of $8.59. The company’s fifty day moving average price is $5.46 and its 200-day moving average price is $5.43. The firm has a market capitalization of $341.41 million, a price-to-earnings ratio of -2.61 and a beta of 2.48.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.17). The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.17 million. Caribou Biosciences had a negative net margin of 296.05% and a negative return on equity of 31.06%. As a group, equities research analysts expect that Caribou Biosciences, Inc. will post -1.76 EPS for the current year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.